Washington Legal Foundation To Keep Eye On FDA’s Ad Division With “DDMAC Watch”
This article was originally published in The Pink Sheet Daily
Executive Summary
WLF will consider litigation against FDA in the case of inappropriate trends in the ad division’s warning and untitled letters. The program’s “rapid response” component will send responses to DDMAC letters specifically addressing “legally deficient or ill-advised” citations.